Alve60 mg

Alve 60 mg is indicated in- Irritable Bowel Syndrome Bowel movement disturbances caused by small sacs or pouches in the wall of the gut (diverticular disease) Abdominal pain associated with menstrual periods (Primary dysmenorrhea) Relief of other conditions associated with spasm of involuntary muscle

Anticholinergics

Alve 60 mg is an anti-spasmodic medicine. It relaxes the muscles in the intestine (gut) and uterus (womb). This helps to stop the pain when the muscles become tense.

The usual dose is 60-120 mg 3 times a day.

Adult: Orally: 60-120 mg 1-3 times daily.

There are no drug interactions reported with this medicine.

Paralytic ileus or known hypersensitivity to any of the ingredients.

Possible side effects may include nausea, headache, dizziness, itching, rash and allergic reactions.

The safety of Alve 60 mg during pregnancy and breastfeeding is not established. It is not recommended for use during pregnancy or breastfeeding.

Avoid Alve 60 mg in patients with intestinal obstruction or paralytic ileus.

Can produce hypotension and atropine like-toxic effects. Management for overdose is as like as atropine poisoning with continuation of supportive therapy for hypotension.

Store in a cool and dry place, away from light. Keep all medicines out of the reach of children. Store below 25°C temperature.

Alve 60 mg is not suitable for children under 12 years old.

Anticholinergics

Alve 60 mg is a smooth muscle relaxant. Smooth muscle is a type of muscle that is not under voluntary control; it is the muscle present in places such as the gut and uterus. Alve 60 mg acts directly on the muscle in the gut, causing it to relax. This prevents the muscle spasm which occur in the gut in conditions such as irritable bowel syndrome and diverticular disease. Alve 60 mg also relaxes the smooth muscle in the uterus. It is therefore also used to treat painful menstruation, which is caused by muscle spasm in the uterus (dysmenorrhea).

Although no teratogenic effects have been reported, use during pregnancy or lactation is not recommended as evidence of safety in preclinical studies are limited.

Children under 12 years: Not recommended